Therapeutic Advances in GI Cancers: Immuno-Oncology and Beyond

This symposium was developed and funded by Bristol Myers Squibb.

At the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, the latest advancements in immunotherapy for colorectal cancer, gastroesophageal cancers, and hepatocellular carcinoma were presented.

Topics covered:

• The role of immunotherapy in patients with high microsatellite instability colorectal cancer, highlighting data from the CheckMate 8HW and NICHE-2 trials.
• Insight into the use of immunotherapy-based regimens for gastroesophageal cancers, including treatment considerations based on key biomarkers and emerging treatment options.
• Results from several trials, including IMbrave150, HIMALAYA, and CheckMate 9DW, supporting the increasing role of immunotherapy combinations in first-line hepatocellular carcinoma treatment.

Colorectal Cancer: Novel Combination Therapies

Gastroesophageal Cancers: the Role of Immunotherapy

Hepatocellular Carcinoma: First-line Treatment Options in the Metastatic Setting

1. Head of Oncology 3 Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
2. Medical Oncology Department, Valencia University Clinical Hospital – INCLIVA, Valencia, Spain
3. Professor in Hepatology, Head of Hepato-Gastroenterology and Digestive Oncology Department, University Grenoble-Alpes, France